Investigational new drug approval of DA-1241: what we know about GPR119 targeting for MASH therapy?

Al Smadi, Khaled; Qureshi, Ammar; Ashouri, Besher; Kayali, Zeid

Al Smadi, Khaled; Qureshi, Ammar; Ashouri, Besher; Kayali, Zeid.

Affiliation

Al Smadi K; Department of Gastroenterology and Hepatology, University of California - Riverside School of Medicine, Rialto, CA, USA.
Qureshi A; Department of Gastroenterology and Hepatology, University of California - Riverside School of Medicine, Rialto, CA, USA.
Ashouri B; Department of Gastroenterology and Hepatology, University of California - Riverside School of Medicine, Rialto, CA, USA.
Kayali Z; Department of Gastroenterology and Hepatology, University of California - Riverside School of Medicine, Rialto, CA, USA.

Expert Opin Investig Drugs ; 33(9): 877-880, 2024 Sep.

Article de En | MEDLINE | ID: mdl-39092979

Sujet(s)
Mots clés

GPR119 agonists; MASH; MASLD; Pharmacotherapy

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Médicaments en essais cliniques / Agrément de médicaments / Récepteurs couplés aux protéines G Limites: Animals / Humans Langue: En Journal: Expert Opin Investig Drugs Sujet du journal: TERAPIA POR MEDICAMENTOS Année: 2024 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google